ArticleBritish journal of cancer2024

Phase 1b study of enzalutamide plus CC-115, a dual mTORC1/2 and DNA-PK inhibitor, in men with metastatic castration-resistant prostate cancer (mCRPC).

Jimmy L Zhao et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.